These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27261196)

  • 21. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
    Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
    Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells.
    Ohtani H; Ikegawa T; Honda Y; Kohyama N; Morimoto S; Shoyama Y; Juichi M; Naito M; Tsuruo T; Sawada Y
    Pharm Res; 2007 Oct; 24(10):1936-43. PubMed ID: 17492365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 4-methylumbelliferone on cell-free synthesis of hyaluronic acid.
    Nakamura T; Funahashi M; Takagaki K; Munakata H; Tanaka K; Saito Y; Endo M
    Biochem Mol Biol Int; 1997 Oct; 43(2):263-8. PubMed ID: 9350333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line.
    Natazuka T
    Kobe J Med Sci; 1992 Dec; 38(6):347-63. PubMed ID: 1284834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice.
    Piccioni F; Malvicini M; Garcia MG; Rodriguez A; Atorrasagasti C; Kippes N; Piedra Buena IT; Rizzo MM; Bayo J; Aquino J; Viola M; Passi A; Alaniz L; Mazzolini G
    Glycobiology; 2012 Mar; 22(3):400-10. PubMed ID: 22038477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone.
    Kakizaki I; Kojima K; Takagaki K; Endo M; Kannagi R; Ito M; Maruo Y; Sato H; Yasuda T; Mita S; Kimata K; Itano N
    J Biol Chem; 2004 Aug; 279(32):33281-9. PubMed ID: 15190064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
    Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
    Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
    Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
    Lokeshwar VB; Lopez LE; Munoz D; Chi A; Shirodkar SP; Lokeshwar SD; Escudero DO; Dhir N; Altman N
    Cancer Res; 2010 Apr; 70(7):2613-23. PubMed ID: 20332231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
    Acharya S; Sahoo SK
    J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells.
    Saito T; Tamura D; Nakamura T; Makita Y; Ariyama H; Komiyama K; Yoshihara T; Asano R
    Oncol Rep; 2013 Jan; 29(1):335-42. PubMed ID: 23124556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
    Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.